Observing Bempedoic Acid and Ezetimibe Use in Adults with High Cholesterol
Observes real-world use of bempedoic acid, alone or with ezetimibe, in adults with high cholesterol.
Plain-language title generated from the registry record
Registry title: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Key facts
- Where
- Belo Horizonte, Blumenau, Caixias Do Sul, Campina Grande do Sul, Curitiba, Joinville, Juiz de Fora, Maringá, Pocos de Calda, Porto Alegre, Salvador, Santo André, São Paulo, and Tatuí, BrazilSee the 23 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high cholesterol (primary hypercholesterolaemia) or mixed dyslipidaemia who take or will take bempedoic acid, or its single pill with ezetimibe, in routine care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Documented primary hypercholesterolaemia or mixed dyslipidaemia
- Earlier treatment
- People already on bempedoic acid or its single pill with ezetimibe must have started it no more than three months before joining.
Main reasons for not taking part
- Not signing written informed consent
- Having a contraindication listed in the product information (SmPC) of bempedoic acid or its single pill with ezetimibe
- Taking part in another interventional study at the same time
- Life expectancy of 1 year or less
Read by machine on 12 November 2026.
Where in Brazil
- Hospital Felicio RochoBelo Horizonte, BrazilContact: Principal InvestigatorTaking people
- Hospital Mater Dei ContornoBelo Horizonte, BrazilContact: Principal InvestigatorTaking people
- Hospital Vera CruzBelo Horizonte, BrazilContact: Principal InvestigatorTaking people
- Clinica Procardio Ltda.Blumenau, BrazilContact: Principal InvestigatorTaking people
- Universidade de Caxias do Sul (UCS)Caixias Do Sul, BrazilContact: Principal InvestigatorTaking people
- Hospital e Maternidade Angelina CaronCampina Grande do Sul, BrazilContact: Principal InvestigatorTaking people
- Pontificia Universidade Catolica do Parana-(PUCPR)Curitiba, BrazilContact: Principal InvestigatorTaking people
- CMEP Centro Multidisciplinar de Ensino Especializado e Pesquisa LtdaJoinville, BrazilContact: Principal InvestigatorTaking people
- Galileo Medical Research Ltda.Juiz de Fora, BrazilContact: Principal InvestigatorTaking people
- Hospital Parana - Parana Medical Research CenterMaringá, BrazilContact: Principal InvestigatorTaking people
- Hospital Maternidade e Pronto Socorro Santa LuciaPocos de Calda, BrazilContact: Principal InvestigatorTaking people
- Hospital Moinhos de Vento (HMV)Porto Alegre, BrazilContact: Principal InvestigatorTaking people
- Fundação Bahiana de InfectologiaSalvador, BrazilContact: Principal InvestigatorTaking people
- Hospital da Mater Dei SalvadorSalvador, BrazilContact: Principal InvestigatorTaking people
- Hospital E Maternidade Dr. Cristavao da Gama (HMCG)Santo André, BrazilContact: Principal InvestigatorTaking people
- BP - A Beneficência Portuguesa de São PauloSão Paulo, BrazilContact: Principal InvestigatorTaking people
- Cardial Servicos Medicos EspecializadosSão Paulo, BrazilContact: Principal InvestigatorTaking people
- FGM Clinica Paulista De Doencas Cardiovasculares (IPDC)São Paulo, BrazilContact: Principal InvestigatorTaking people
- Hospital Alemao Oswaldo Cruz (HAOC)São Paulo, BrazilContact: Principal InvestigatorTaking people
- Instituto Conceive LtdaSão Paulo, BrazilContact: Principal InvestigatorTaking people
- Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - InCor HCFMUSPSão Paulo, BrazilContact: Principal InvestigatorTaking people
- Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de MedicinaSão Paulo, BrazilContact: Principal InvestigatorTaking people
- Instituto de Moléstias Cardiovasculares TatuíTatuí, BrazilContact: Principal InvestigatorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT07206472
- Record updated
- 19 October 2026
- Original description
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.Read full original descriptionShow less
A Multi-national, Non-interventional Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Patients can be enrolled, when they fulfil the following inclusion criteria:; Written informed consent to participate; At least 18 years of age; Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid/ FDC with ezetimibe at the discretion of the physician are appropriate for participation in the observation; For patients who are treated with bempedoic acid/FDC with ezetimibe prior to signed informed consent, initiation of bempedoic acid/FDC with ezetimibe must be within a maximum of three months prior to inclusion; No contraindications exist according to the SmPC of bempedoic acid/FDC with ezetimibe; No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible); Life expectancy > 1 year; No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.